Defence Announces Dr. Maxime Parisotto as CSO, Director of Science and Business Development
Defence Therapeutics has appointed Dr. Maxime Parisotto as Chief Scientific Officer, Director of Science and Business Development. Dr. Parisotto brings over 20 years of experience in biochemistry, drug development, and innovation, holding a PhD focused on breast cancer and metabolism. His background includes postdoctoral fellowships at IGBMC and Université de Montréal, and a senior analyst role at adMare Bioinnovations. He will complete his MBA from Sherbrooke University in April 2025. The company has granted him 100,000 incentive stock options, exercisable at 60 cents per share for three years. The announcement also notes that Dr. Moutih Rafei has left the company.
Defence Therapeutics ha nominato il Dott. Maxime Parisotto come Chief Scientific Officer e Direttore della Scienza e dello Sviluppo Commerciale. Il Dott. Parisotto porta con sé oltre 20 anni di esperienza in biochimica, sviluppo di farmaci e innovazione, avendo conseguito un dottorato di ricerca incentrato sul cancro al seno e sul metabolismo. La sua carriera include incarichi post-dottorali presso l'IGBMC e l'Université de Montréal, nonché un ruolo di analista senior presso adMare Bioinnovations. Completando il suo MBA presso l'Università di Sherbrooke nell'aprile del 2025. L'azienda gli ha assegnato 100.000 opzioni stock incentive, esercitabili a 60 centesimi per azione per tre anni. L'annuncio precisa anche che il Dott. Moutih Rafei ha lasciato l'azienda.
Defence Therapeutics ha nombrado al Dr. Maxime Parisotto como Director Científico y Director de Ciencia y Desarrollo Empresarial. El Dr. Parisotto aporta más de 20 años de experiencia en bioquímica, desarrollo de medicamentos e innovación, con un doctorado centrado en el cáncer de mama y el metabolismo. Su experiencia incluye becas postdoctorales en el IGBMC y la Université de Montréal, así como un papel de analista senior en adMare Bioinnovations. Completarà su MBA en la Universidad de Sherbrooke en abril de 2025. La empresa le ha otorgado 100,000 opciones de acciones como incentivo, que se pueden ejercer a 60 centavos por acción durante tres años. El anuncio también indica que el Dr. Moutih Rafei ha dejado la empresa.
Defence Therapeutics는 Maxime Parisotto 박사를 최고 과학 책임자이자 과학 및 비즈니스 개발 이사로 임명했습니다. Parisotto 박사는 20년 이상의 생화학, 약물 개발 및 혁신 경험을 보유하고 있으며, 유방암 및 대사에 중점을 둔 박사 학위를 가지고 있습니다. 그의 경력에는 IGBMC 및 몬트리올 대학에서의 박사후 연구원 경력이 있으며, adMare Bioinnovations에서 선임 분석가로 활동했습니다. 그는 2025년 4월 셔브룩 대학교에서 MBA를 마칠 예정입니다. 회사는 그에게 100,000개의 유인 스톡 옵션을 부여하였으며, 이는 주당 60센트로 3년간 행사할 수 있습니다. 이 발표에서는 Moutih Rafei 박사가 회사를 떠났다는 내용도 언급하고 있습니다.
Defence Therapeutics a nommé le Dr Maxime Parisotto au poste de directeur scientifique et directeur de la science et du développement commercial. Le Dr Parisotto apporte plus de 20 ans d'expérience en biochimie, développement de médicaments et innovation, avec un doctorat axé sur le cancer du sein et le métabolisme. Son parcours inclut des bourses postdoctorales à l'IGBMC et à l'Université de Montréal, ainsi qu'un rôle d'analyste senior chez adMare Bioinnovations. Il complétera son MBA à l'Université de Sherbrooke en avril 2025. L'entreprise lui a accordé 100 000 options d'achat d'actions incitatives, exerçables à 60 cents par action pendant trois ans. L'annonce précise également que le Dr Moutih Rafei a quitté l'entreprise.
Defence Therapeutics hat Dr. Maxime Parisotto zum Chief Scientific Officer und Direktor für Wissenschaft und Geschäftsentwicklung ernannt. Dr. Parisotto bringt über 20 Jahre Erfahrung in Biochemie, Arzneimittelentwicklung und Innovation mit und hat einen Doktortitel, der sich auf Brustkrebs und Stoffwechsel konzentriert. Zu seinem Werdegang gehören Postdoc-Stellen am IGBMC und an der Université de Montréal sowie eine Position als leitender Analyst bei adMare Bioinnovations. Er wird sein MBA-Studium an der Universität Sherbrooke im April 2025 abschließen. Das Unternehmen hat ihm 100.000 Anreiz-Aktienoptionen gewährt, die für drei Jahre zu 60 Cent pro Aktie ausgeübt werden können. In der Mitteilung wird auch erwähnt, dass Dr. Moutih Rafei das Unternehmen verlassen hat.
- Appointment of experienced CSO with 20+ years in drug development and innovation
- New CSO brings dual expertise in scientific research and business development
- Extensive professional network in biotech ecosystem
- Departure of previous scientific leadership (Dr. Moutih Rafei)
- Stock option grant of 100,000 shares may cause minor dilution
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that Dr. Maxime Parisotto has joined the Company as Chief Scientific Officer, Director of Science and Business Development.
Dr. Maxime Parisotto is a seasoned biochemist with over 20 years of experience spanning academic research, drug development, and innovation. He holds a PhD in biochemistry focused on breast cancer and metabolism and has held postdoctoral fellowships at prestigious institutions, including the IGBMC in Strasbourg, France, and the Université de Montréal. As Senior Analyst, he contributed to significant investment decisions at adMare Bioinnovations. He also holds a graduate certificate in life science entrepreneurship development from Concordia university and will be graduating with an MBA from Sherbrooke University in April 2025.
Dr. Parisotto has a robust track record of leadership, including managing multidisciplinary teams, contributing to high-impact scientific publications. Before joining adMare, he led research initiatives in cancer biology and stem cells at institutions such as the IRCM and Université de Montréal. He is an active member of the Canadian biotech ecosystem, with an extensive professional network contacts and regular participation in national and international conferences. His research and business interests focus on advancing drug development from discovery to clinical stages and fostering collaborations between academia, industry, and investors to drive innovation in biopharmaceuticals. His scientific expertise's are mainly in oncology, protein biochemistry, cell metabolism and stem cells biology.
"I am honored and excited to join Defence Therapeutics as CSO, Director of Science & Business Development. I strongly believe that Defence's proprietary Accum® technology platform has a great potential for the development of targeted therapies that will make a difference for the patients," mentioned Dr. Maxime Parisotto.
"We are proud to welcome Dr. Maxime Parisotto as he is an accomplished and strong scientist with a mission to focus on the scientific programs that will increase the value of Defence Therapeutics. His business knowledge is definitely an important aspect that will guide and inspire the Company's growth and development for the benefit of Defence's shareholders," mentioned Sébastien Plouffe, President, CEO and Founder of Defence Therapeutics.
The Company has granted 100,000 incentive stock options to Dr. Parisotto, in accordance with the terms and conditions of Defence's stock option plan. Each stock option vests immediately and is exercisable at a price of 60 cents per share for a period of three years from the grant date.
Defence would like to mention that Dr. Moutih Rafei is no longer with the Company. The Company would like to thank Dr. Rafei for his contributions.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231144
FAQ
Who is the new CSO of Defence Therapeutics (DTCFF)?
What are Dr. Parisotto's qualifications at Defence Therapeutics (DTCFF)?
What stock options were granted to the new CSO of Defence Therapeutics (DTCFF)?
